ArticleCancer gene therapy2002

Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.

Christina Voelkel-Johnson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.